TNX-102 SL: Ph II AtEase data

The double-blind, U.S Phase II AtEase trial in 231 patients with military-related PTSD showed that once-daily 2.8 mg sublingual TNX-102 SL given at bedtime missed the primary endpoint

Read the full 289 word article

User Sign In